AVIR

Peers: ENTA ASMB ABUS VIR ALGS COCP IVVD TRAW AIM SNGX

| Held by: VTI IWM VXF IWN DFAS VTWO IBB SCHA DFMC IWC

Index	RUT
Market Cap	328.84M
Enterprise Value	109.79M
Income	-165.29M
Sales	0.00M
Book/sh	2.55
Cash/sh	2.74
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	55
IPO	Oct 30, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.61
P/C	1.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.13
Current Ratio	8.13
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.09
EPS next Y	-1.48
EPS next Q	-0.51
EPS this Y	-2.32%
EPS next Y	25.44%
EPS next 5Y	12.05%
EPS past 3/5Y	-11.75% -71.02%
Sales past 3/5Y	- -
EPS Y/Y TTM	-29.71%
Sales Y/Y TTM	-
EPS Q/Q	7.28%
Sales Q/Q	-
Earnings	Nov 09 AMC
EPS/Sales Surpr.	26.13% -

Insider Own	20.46%
Insider Trans	0.04%
Inst Own	71.85%
Inst Trans	-0.47%
ROA	-52.99%
ROE	-58.14%
ROIC	-80.96%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.91%
SMA50	-18.27%
SMA200	-16.87%
Trades

Shs Outstand	80.20M
Shs Float	63.79M
Short Float	4.81%
Short Ratio	10.93
Short Interest	3.07M
52W High	6.45 -36.43%
52W Low	2.87 42.86%
Volatility	5.92% 5.62%
ATR (14)	0.24
RSI (14)	32.06
Beta	0.72
Rel Volume	0.00
Avg Volume	281.01K
Volume	0

Perf Week	-1.44%
Perf Month	-20.08%
Perf Quarter	-12.77%
Perf Half Y	-28.07%
Perf YTD	14.85%
Perf Year	26.15%
Perf 3Y	30.57%
Perf 5Y	-65.02%
Perf 10Y	-
Recom	1.67
Target Price	8.50
Prev Close	4.10
Price	4.10
Change %	0.00%

Consensus

Buy

Avg. Price Target

$8.50

Implied Upside

+107.3%

Analysts5incl. previous ratings

Rating Distribution2 Buy · 2 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 13, 2024	Upgrade	MMorgan Stanley	Underweight → Equal-Weight	$2 → $6.88	+67.8%
Aug 10, 2023	Downgrade	JJP Morgan	Neutral → Underweight
Jan 06, 2022	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$14 → $7	+70.7%
Nov 18, 2021	Downgrade	SSVB Leerink	Outperform → Mkt Perform
Oct 20, 2021	Downgrade	JJP Morgan	Overweight → Neutral	$61 → $16	+290.2%
Oct 05, 2021	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$55	+1,241.5%
Nov 25, 2020	Initiated	EEvercore ISI	Outperform
Nov 24, 2020	Initiated	WWilliam Blair	Outperform	$60	+1,363.4%
Nov 24, 2020	Initiated	MMorgan Stanley	Overweight	$49	+1,095.1%
Nov 24, 2020	Initiated	JJP Morgan	Overweight	$45	+997.6%

Nov-02-26 04:05PM	Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026 (GlobeNewswire)
Sep-08-26 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-26 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-26 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 (GlobeNewswire)
Jul-29-26 07:00AM	FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimers data (BioPharma Dive)
07:00AM	Loading…
Jul-28-26 07:00AM	Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus (GlobeNewswire) -6.43%
Jul-14-26 07:00AM	Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus (GlobeNewswire)
Jun-25-26 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
May-27-26 07:00AM	Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 (GlobeNewswire)
May-13-26 07:00AM	Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline (GlobeNewswire) -16.91%
01:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
May-12-26 04:05PM	Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-05-26 07:00AM	Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 (GlobeNewswire)
Mar-06-26 12:02AM	Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ... (GuruFocus.com) +11.13%
Mar-05-26 06:47PM	Atea Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) +6.43%
04:05PM	Loading…
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 (GlobeNewswire)
Feb-24-26 07:00AM	Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 (GlobeNewswire)
Jan-19-26 11:19AM	JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens (Pharmaceutical Technology)
Jan-15-26 02:32PM	Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference (MarketBeat)
Jan-09-26 07:17AM	Atea Pharmaceuticals to highlight strategic priorities for FY26 (TipRanks)
Jan-08-26 07:00AM	Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-26 07:00AM	Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-25 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
Dec-02-25 04:46PM	ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman (Exec Edge)
Nov-19-25 08:02PM	Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... (GuruFocus.com)
07:00AM	Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-12-25 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -12.57%
Nov-07-25 08:00AM	Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 (GlobeNewswire)
Nov-05-25 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 (GlobeNewswire)
07:00AM	Loading…
Oct-22-25 07:00AM	Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 (GlobeNewswire)
Sep-02-25 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-07-25 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 (GlobeNewswire)
Jun-24-25 07:00AM	Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America (GlobeNewswire)
May-12-25 04:11PM	Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.82% -11.15%
May-07-25 07:00AM	Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 (GlobeNewswire)
May-01-25 07:00AM	Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 (GlobeNewswire)
Apr-23-25 07:00AM	Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 (GlobeNewswire)
Apr-17-25 07:00AM	Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program (GlobeNewswire)
Apr-09-25 07:00AM	Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
Mar-26-25 01:58PM	Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value (GlobeNewswire)
08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Mar-21-25 05:54PM	Atea Pharmaceuticals Issues Statement Regarding Director Nominations (GlobeNewswire)
08:25AM	Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory (InsiderMonkey)
Mar-19-25 07:00AM	Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 (GlobeNewswire)
Mar-07-25 12:46PM	Q4 2024 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:17AM	Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ... (GuruFocus.com)
Mar-06-25 04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors (GlobeNewswire)
Jan-13-25 07:00AM	Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 07:00AM	Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 05:05PM	Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process (Business Wire)
Dec-16-24 05:00AM	Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships (GlobeNewswire) +5.80%
Dec-05-24 07:06AM	Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir (TipRanks) -5.94%
Dec-04-24 03:14PM	After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study (Benzinga) -10.49%
07:00AM	Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) (GlobeNewswire)
06:09AM	Atea plans Phase 3 study for hepatitis C drug after mid-stage results (BioPharma Dive)
Nov-26-24 07:00AM	Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-22-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-15-24 11:00AM	Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Nov-11-24 08:01PM	Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com)
Nov-07-24 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (GlobeNewswire)
Oct-30-24 07:00AM	Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Oct-16-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks) +6.20%
Oct-09-24 05:19PM	Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Oct-04-24 09:35AM	Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-30-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-13-24 02:53PM	Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus (Benzinga) +5.45%
07:00AM	Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 (GlobeNewswire)
Aug-28-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks)
07:00AM	Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway (GlobeNewswire)
Aug-12-24 12:00PM	All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy (Zacks)
09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-07-24 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.03%
Jul-31-24 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.04%
May-29-24 07:00AM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-24 07:00AM	Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.82%
May-15-24 09:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com) -6.31%
May-14-24 04:05PM	Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 07:00AM	Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 (GlobeNewswire)
Mar-27-24 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients (GlobeNewswire) +6.10%
Feb-29-24 10:03AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:58PM	Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-24 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 (GlobeNewswire)
Jan-10-24 09:30AM	Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study (Zacks)
Jan-08-24 04:05PM	Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 (GlobeNewswire) +11.29%
Jan-03-24 07:00AM	Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 07:00AM	Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 03:57PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.12%
05:48AM	Q3 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lucidi Bruno	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	142,350	Jun 23 05:00 PM
BERGER FRANKLIN M	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	536,097	Jun 23 05:00 PM
DUNCAN BARBARA GAYLE	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	92,350	Jun 23 05:00 PM
Polsky Bruce	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	124,806	Jun 23 05:00 PM
Murphy Polly A.	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	121,745	Jun 23 05:00 PM
Adams Jerome M.	Director	Jun 18 '26	Option Exercise	0.00	29,600	0	92,350	Jun 23 05:00 PM
Corcoran Andrea	See Remarks	Mar 11 '26	Option Exercise	1.24	60,000	74,400	823,576	Mar 13 06:00 PM
Sommadossi Jean-Pierre	President, CEO, and Chairman	Feb 03 '26	Option Exercise	1.24	300,000	372,000	767,830	Feb 03 07:46 PM

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

FounderDr. Jean-Pierre Sommadossi Ph.D.

CFOMs. Andrea J. Corcoran J.D.

Chief Commercial OfficerMr. John F. Vavricka

Ph.D.Dr. Janet M. J. Hammond M.D.

Chief Medical OfficerDr. Maria Arantxa Horga M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Atea Pharmaceuticals Inc

Upgrade your Finviz experience